Discovery of cyanovirin-N, a novel human immunodeficiency virus- inactivating protein that binds viral surface envelope glycoprotein gp120: Potential applications to microbicide development

Antimicrobial Agents and Chemotherapy

Volumn 41, Issue 7, 1997, Pages 1521-1530

  Boyd, Michael R ^a,f   Gustafson, Kirk R ^a   McMahon, James B ^a   Shoemaker, Robert H ^a   O'Keefe, Barry R ^a   Mori, Toshiyuki ^a   Gulakowski, Robert J ^a   Wu, Lin ^a   Rivera, Maria I ^a   Laurencot, Carolyn M ^a   Currens, Michael J ^a   Cardellina II, John H ^a   Buckheit Jr , Robert W ^b   Nara, Peter L ^c   Pannell, Lewis K ^d   Sowder II, Raymond C ^e   Henderson, Louis E ^e  

^a Division of Cancer Treatment and Diagnosis   (United States)

^b SOUTHERN RESEARCH INSTITUTE   (United States)

^c NATIONAL CANCER INSTITUTE   (United States)

^d NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

^e SAIC FREDERICK INC   (United States)

^f DTP   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; CYANOVIRIN N; GLYCOPROTEIN GP 120; UNCLASSIFIED DRUG;

ANTIVIRAL ACTIVITY; ARTICLE; CELL FUSION; CONCENTRATION RESPONSE; CONTROLLED STUDY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 2; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; NOSTOC; PERIPHERAL LYMPHOCYTE; PRIORITY JOURNAL; SIMIAN IMMUNODEFICIENCY VIRUS; VIRUS CELL INTERACTION; VIRUS ENVELOPE; VIRUS INHIBITION; VIRUS TRANSMISSION;

EID: 0030790094     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/aac.41.7.1521     Document Type: Article

References (81)

1. Andreu, A., A. E. Stapleton, C. L. Fennell, S. L. Hillier, and W. E. Stamm. 1995. Hemagglutination, adherence, and surface properties of vaginal Lactobacillus species. J. Infect. Dis. 171:1237-1243.
2. Balter, M. 1994. UN Readies new global AIDS plan. Science 266:1312-1313.
3. Barbas, C. F., III, E. Björling, F. Chiodi, N. Dunlop, D. Cababa, T. M. Jones, S. L. Zebedee, M. A. A. Persson, P. L. Nara, E. Norrby, and D. R. Burton. 1992. Recombinant human Fab fragments neutralize human type 1 immunodeficiency virus in vitro. Proc. Natl. Acad. Sci. USA 89:9339-9343.
4. Bates, P. 1996. Chemokine receptors and HIV-1: an attractive pair. Cell 86:1-3.
5. Beutler, J. A., T. C. McKee, R. W. Fuller, M. Tischler, J. H. Cardellina, II, T. G. McCloud, K. M. Snader, and M. R. Boyd. 1993. Frequent occurrence of HIV-inhibitory sulfated polysaccharides in marine invertebrates. Antiviral Chem. Chemother. 4:167-172.
6. Boyd, M. R. 1988. Strategies for the identification of new agents for the treatment of AIDS: a national program to facilitate the discovery and preclinical development of new drug candidates for clinical evaluation, p. 305-319. In V. T. DeVita, S. Hellman, and S. A. Rosenberg (ed.), AIDS, etiology, diagnosis, treatment and prevention. Alan Liss, New York, N.Y.
7. Bryan, R. A., I. Sekigawa, S. M. Chanow, J. S. Johnson, T. J. Gregory, D. J. Capon, and J. E. Groopman. 1989. Characterization of in vitro inhibition of human immunodeficiency virus by purified recombinant CD4. J. Virol. 63: 4370-4375.
8. Buckheit, R. W., Jr. Unpublished observations.
9. Buckheit, R. W., Jr., V. Fliakas-Boltz, W. D. Decker, J. L. Roberson, C. A. Pyle, E. L. White, B. J. Bowden, J. B. McMahon, M. R. Boyd, J. P. Bader, D. G. Nickell, H. Barth, and T. K. Antonucci. 1994a. Biological and biochemical anti-HIV activity of the benzothiadiazine class of nonnucleoside reverse transcriptase inhibitors. Antiviral Res. 25:43-56.
10. Buckheit, R. W., Jr., J. L. Roberson, C. Lackman-Smith, J. R. Wyatt, T. A. Vickers, and D. J. Ecker. 1994b. Potent and specific inhibition of HIV envelope-mediated cell fusion and virus binding by G quartet-forming oligonucleotide (ISIS 5320). AIDS Res. Hum. Retroviruses 10:1497-1506.
11. Burton, D. R., C. F. Barbas, M. A. A. Persson, S. Koenig, R. M. Chanock, and R. A. Lerner. 1991. A large array of human monoclonal antibodies to HIV-1 from combinatorial libraries of asymptomatic seropositive individuals. Proc. Natl. Acad. Sci. USA 88:10134-10137.
12. Burton, D. R., J. Pyati, R. Koduri, S. J. Sharp, G. B. Thornton, P. W. H. I. Parrer, L. S. W. Sawyer, R. M. Hendry, N. Dunlop, P. L. Nara, M. Lamacchis, E. Garraty, E. R. Steihm, Y. J. Bryson, Y. Cao, J. P. Moore, D. D. Ho, and C. F. Barbas III. 1994. Efficient neutralization of primary isolates of HIV-1 by a recombinant human monoclonal antibody. Science 266:1024-1027.
13. Cardellina, J. H., II, M. H. G. Munro, R. W. Fuller, K. M. Manfredi, T. C. McKee, M. Tischler, H. R. Bokesch, K. R. Gustafson, J. A. Beutler, and M. R. Boyd. 1993. A chemical screening strategy for the secondary dereplication and prioritization of HIV-inhibitory aqueous natural products extracts. J. Nat. Prod. 56:1123-1129.
14. Chackerian, B., E. M. Long, P. A. Luciw, and J. Overbaugh. 1997. Human immunodeficiency virus type 1 coreceptors participate in postentry stages in the virus replication cycle and function in simian immunodeficiency virus infection. J. Virol. 71:3932-3939.
15. Chang, H. 1996. Genetic engineering to enhance microbial interference and related therapeutic applications. Nature Biotechnol. 14:444-447.
16. Chen, Z., P. Zhou, D. D. Ho, N. R. Landau, and P. A. Marx. 1997. Genetically divergent strains of simian immunodeficiency virus use CCR5 as a coreceptor for entry. J. Virol. 71:2705-2714.
17. Ciminale, V., B. K. Felber, M. Campbell, and G. N. Pavlakis. 1990. A bioassay for HIV-1 based on Env-CD4 interaction. AIDS Res. Hum. Retroviruses 6:1281-1287.
18. Cohen, J. 1997. Exploiting the HIV-chemokine nexus. Science 275:1261-1264.
19. Collman, R., J. W. Balliet, S. A. Gregory, H. Friedman, D. L. Kolson, N. Nathanson, and A. Srinivasan. 1992. An infectious molecular clone of an unusual macrophage-tropic and highly cytopathic strain of human immunodeficiency virus type 1. J. Virol. 66:7517-7521.
20. Currens, M. J., R. J. Gulakowski, J. M. Mariner, R. A. Moran, R. W. Buckheit, Jr., K. R. Gustafson, J. B. McMahon, and M. R. Boyd. 1996. Antiviral activity and mechanism of action of calanolide A against the human immunodeficiency virus. J. Pharmacol. Exp. Ther. 279:645-651.
21. Currens, M. J., J. Mariner, J. B. McMahon, and M. R. Boyd. 1996. Kinetic analysis of inhibition of HIV-1 reverse transcriptase by calanolide A. J. Pharmacol. Exp. Ther. 279:652-661.
22. Dean, M., M. Carrington, C. Winkler, G. A. Huttley, M. W. Smith, R. Allikmets, J. J. Goedert, S. P. Buchbinder, E. Vittinghoff, E. Gomperts, S. Donfield, D. Vlahov, R. Kaslow, A. Saah, C. Rinaldo, and R. Detels. 1996. Genetic restriction of HIV-1 infection and progression to AIDS by a deletion allele of the CKR5 structural gene. Science 273:1856-1862.
23. D'Souza, M. P., P. Durda, C. V. Hanson, and G. Milman. 1991. Evaluation of monoclonal antibodies to HIV-1 by neutralization and serological assays: an international collaboration. AIDS 5:1061-1070.
24. Elias, C. J., and C. Coggins. 1996. Female-controlled methods to prevent sexual transmission of HIV. AIDS 10(Suppl. 3):543-551.
25. Elmer, G. W., C. M. Surawicz, and L. V. McFarland. 1996. Biotherapeutic agents: a neglected modality for the treatment and prevention of selected intestinal and vaginal infections. JAMA 275:870-876.
26. Endres, M. J., P. R. Clapham, M. Marsh, M. Ahiya, J. D. Turner, A. McKnight, J. F. Thomas, B. Stoebenau-Haggarty, S. Choe, P. J. Vance, T. N. C. Wells, C. A. Power, S. S. Sutterwala, R. W. Doms, N. R. Landau, and J. A. Hoxie. 1996. CD4-independent infection by HIV-2 is mediated by fusin/CXCR4. Cell 87:745-756.
27. Essex, M. 1996. Retroviral vaccines: challenges for the developing world. AIDS Res. Hum. Retroviruses 12:361-363.
28. Gartner, S., P. Markovits, D. M. Markovitz, M. H. Kaplan, R. C. Gallor, and M. Popovic. 1986. The role of mononuclear phagocytes in HTLV-III/LAV infection. Science 233:215-219.
29. Gartner, S., and M. Popovic. 1990. Virus isolation and production, p. 59-63. In A. Aldovini and B. Walker (ed.), Techniques in HIV research. Stockton Press, New York, N.Y.
30. Gendelman, H. E., J. M. Orenstein, L. M. Baca, B. Weiser, H. Burger, D. C. Kalter, and M. S. Meltzer. 1989. The macrophage in the persistence and pathogenesis of HIV infection. AIDS 3:475-495.
31. Gorny, M. K., J.-Y. Xu, V. Gianakakos, S. Karawowska, C. Williams, H. W. Sheppard, C. V. Hanson, and S. Zolla-Pazner. 1991. Production of site-selected neutralizing human monoclonal antibodies against the third variable region of the human immunodeficiency virus type 1 envelope glycoprotein. Proc. Natl. Acad. Sci. USA 88:3238-3242.
32. Gorny, M. K., J.-Y. Xu, S. Karawowska, A. Buchbinder, and S. Zolla-Pazner. 1993. Repertoire of neutralizing human monoclonal antibodies specific for the V3 domain of HIV-1 gp120. J. Immunol. 150:635-643.
33. Gulakowski, R. J., J. B. McMahon, P. G. Staley, R. A. Moran, and M. R. Boyd. 1991. A semiautomated multiparameter assay for anti-HIV drug screening. J. Virol. Methods 33:87-100.
34. Gustafson, K. R., J. H. Cardellina III, R. W. Fuller, O. S. Weislow, R. F. Kiser, K. M. Snader, G. L. Patterson, and M. R. Boyd. 1989. AIDS-antiviral sulfolipids from cyanobacteria (blue-green algae). J. Natl. Cancer Inst. 81: 1254-1258.
35. Hill, C. M., and D. R. Littman. 1996. Natural resistance to HIV? Nature 382:688-699.
36. Hillier, S. L. 1996. A healthy vaginal ecosystem is important for prevention of HIV transmission: why and how?, p. 56 In Program of the NIAID Conference on Advances in AIDS Vaccine Development, 11 to 15 February 1996. National Institute of Allergy and Infectious Diseases, Bethesda, Md.
37. Hols, P., T. Ferain, D. Garmyn, N. Bernard, and J. Delcour. 1994. Use of homologous expression-secretion signals and vector-free stable chromosomal integration in engineering of Lactobacillus plantarum for α-amylase and levanase expression. Appl. Environ. Microbiol. 60:1401-1413.
38. Kelley, K. J. 1996. Using host defense to fight infectious diseases. Nature Biotechnol. 14:587-590.
39. Killington, R. A., and K. L. Powell. 1985. Growth, assay and purification of herpesviruses, p. 207-236. In B. W. J. Mahy (ed.), Virology - a practical approach. IRL Press, Washington, D.C.
40. Kimpton, J., and M. Emerman. 1992. Detection of replication-competent and pseudotyped human immunodeficiency virus with a sensitive cell line on the basis of activation of an integrated β-galactosidase gene. J. Virol. 66: 2232-2239.
41. 4. Nature (London) 227:680-685.
42. Laman, J. D., M. M. Schellekens, Y. F. Abacioglu, G. K. Lewis, M. Tersmette, R. A. M. Fouchier, J. P. M. Langedijk, E. Claassen, and W. J. A. Boersma. 1992. Variant-specific monoclonal and group-specific polyclonal human immunodeficiency virus type 1 neutralizing antibodies raised with specific peptides from the gp120 third variable domain. J. Virol. 66:1823-1831.
43. Laman, J. D., M. M. Schellekens, G. K. Lewis, J. P. Moore, T. J. Matthews, J. P. M. Langedijk, R. H. Meloen, W. J. A. Boersma, and E. Claassen. 1993. A hidden region in the third variable domain of HIV-1 IIIB gp120 identified by a monoclonal antibody. AIDS Res. Hum. Retroviruses 9:605-612.
44. Lange, J. M. A., M. Karam, and P. Piot. 1993. Boost for vaginal microbicides against HIV. Lancet 341:1356.
45. Layne, S. P., M. J. Merges, J. L. Spouge, M. Dembo, and P. Nara. 1991. Blocking of human immunodeficiency virus infection depends on cell density and viral stock age. J. Virol. 65:3293-3300.
46. Leeder, J. S., H. M. Dosch, P. A. Harper, P. Lam, and S. P. Speilberg. 1989. Fluorescence-based viability assay for studies of reactive drug intermediates. Anal. Biochem. 177:364-372.
47. Leer, R. J., N. van-Luijk, M. Posno, and P. H. Pauwels. 1992. Structural and functional analysis of two cryptic plasmids from Lactobacillus pentosus MD353 and Lactobacillus plan. Mol. Gen. Genet. 234:265-274.
48. Liu, R., W. A. Paxton, S. Choe, D. Ceradini, S. R. Martin, R. Horuk, M. E. MacDonald, H. Stuhlmann, R. A. Koup, and N. R. Landau. 1996. Homozygous defect in HIV-1 coreceptor accounts for resistance of some multiply-exposed individuals to HIV-1 infection. Cell 86:367-377.
49. mac 239. J. Virol. 71:2522-2527.
50. Matsushita, S., M. Robert-Guroff, J. Rusche, A. Koito, T. Hattori, H. Hoshino, K. Javaherian, K. Takatsuki, and S. Putney. 1988. Characterization of a human immunodeficiency virus neutralizing monoclonal antibody and mapping of the neutralizing epitope. J. Virol. 62:2107-2114.
51. McGroaorty, J. A. 1993. Probiotic use of lactobacilli in the human female urogenital tract. FEMS Immunol. Med. Microbiol. 6:251-264.
52. Merson, M. H. 1993. Slowing the spread of HIV: agenda for the 1990's. Science 260:1266-1268.
53. Mercenier, A., P. H. Pauwels, and B. M. Chassy. 1994. Genetic engineering of lactobacilli, leuconosotocs and Streptococcus thermophillus, p. 252-294. In M. J. Gasson and W. M. deVos (ed.), Genetics and biotechnology of lactic acid bacteria. Blackie Academic and Professional, Glasgow, United Kingdom.
54. Moore, J. P. 1995. Back to primary school. Nature 376:115.
55. Moore, J. P. 1997. Coreceptors: implications for HIV pathogenesis and therapy. Science 276:51-52.
56. Moore, J. P., Y. Cao, L. Quing, Q. J. Sattentau, J. Pyati, R. Koduri, J. Robinson, C. F. Barbas III, D. R. Burton, and D. D. Ho. 1995. Primary isolates of human immunodeficiency virus type 1 are relatively resistant to neutralization by monoclonal antibodies to gp120 and their neutralization is not predicted by studies with monomeric gp120. J. Virol. 69:101-109.
57. Moore, J. P., B. A. Jameson, R. A. Weiss, and Q. J. Sattentau. 1993. The HIV-cell fusion reaction, p. 233-289. In J. Bentz (ed.), Viral fusion mechanisms. CRC Press, Boca Raton, Fla.
58. Moore, J. P., Q. J. Sattentau, R. Wyatt, and J. Sodroski. 1994. Probing the structure of the human immunodeficiency virus surface glycoprotein gp120 with a panel of antibodies. J. Virol. 68:469-484.
59. Nara, P. L., and P. J. Fischinger. 1988. Quantitative infectivity assay for HIV-1 and -2. Nature 332:469-470.
60. Painter, K. 1996. Researching urgent need for women's and self-protection, p. 4D. USA Today, 10 July 1996.
61. Patterson, G. M., K. K. Baker, C. L. Baldwin, C. M. Bolis, F. R. Caplan, L. K. Larsen, I. A. Levine, R. E. Moore, C. S. Nelson, K. D. Tschappat, G. D. Tuang, M. R. Boyd, J. H. Cardellina II, R. P. Collins, K. R. Gustafson, and K. M. Snader. 1993. Antiviral activity of cultured blue-green algae (cyanophyta). J. Phycol. 29:125-130.
62. Pauwels, R., and E. DeClercq. 1996. Development of vaginal microbicides for the prevention of heterosexual transmission of HIV. J. Acquired Immune Defic. Syndr. 11:211-221.
63. Paxton, W. A., T. Drajic, R. A. Koup, and J. A. Moore. 1996. The β-chemokines, HIV type 1 second receptors and exposed uninfected persons. AIDS Res. Hum. Retroviruses 12:1203-1207.
64. Piot, P., and M. Laga. 1994. Epidemiology of AIDS in the developing world, p. 109-132. In S. Broder, T. C. Merigan, Jr., and G. Bolognesi (ed.), Textbook of AIDS medicine. Williams and Wilkins, Baltimore, Md.
65. Precious, B., and W. C. Russell. 1985. Growth, purification and titration of adenoviruses, p. 193-205. In B. W. J. Mahy (ed.), Virology - a practical approach. IRL Press, Washington, D.C.
66. Roben, P., J. P. Moore, M. Thali, J. Sodroski, C. F. Barbas III and D. R. Burton. 1994. Recognition properties of a panel of human recombinant Fab fragments to the CD4 binding site of gp120 that show differing abilities to neutralize human immunodeficiency virus type 1. J. Virol. 68:4821-4828.
67. Rosenberg, M. J., K. K. Holmes, and The World Health Organization Working Group on Virucides. 1993. Virucides in prevention of HIV infection. Sex. Transm. Dis. 20:41-44.
68. Samson, M., F. Libert, B. J. Doranz, J. Rucker, C. Liesnard, C.-M. Farber, S. Saragosti, C. Lapoumeroulie, J. Cognaux, C. Forceille, G. Muyldermans, C. Verhofstede, G. Burtonboy, M. Georges, T. Imai, S. Rana, Y. Yi, R. J. Smyth, R. G. Collman, R. W. Doms, G. Vassart, and M. Parmentier. 1996. Resistance to HIV-1 infection in Caucasian individuals bearing mutant alleles of the CCR-5 chemokine receptor gene. Nature 382:722-725.
69. Sattentau, Q. J., and J. P. Moore. 1993. The role of CD4 in HIV binding and entry. Phil. Trans. R. Soc. Lond. B 342:59-66.
70. Soto-Ramirez, L. E., B. Renjifo, M. F. McLane, R. Marlink, C. O'Hara, R. Sutthent, C. Wasi, P. Vithayasai, V. Vithayasai, C. Apichartpiyakul, P. Auewarakul, V. P. Cruz, D.-S. Chui, R. Osathanondh, K. Mayer, T.-H. Lee, and M. Essex. 1996. HIV-1 Langerhans' cell tropism associated with heterosexual transmission of HIV. Science 271:1291-1293.
71. Steimer, K. S., G. A. VanNest, N. L. Haigwood, E. M. Tillson, C. George-Nascimento, P. J. Barr, and D. Dina. 1988. Recombinant env and gag polypeptides in characterizing HIV-1 neutralizing antibodies, p. 347-355. In H. Ginsberg, F. Brown, R. A. Lerner, and R. Chanock (ed.), Vaccines 88. Cold Spring Harbor Laboratories, Cold Spring Harbor, N.Y.
72. Sullivan, N., Y. Sun, J. Li, W. Hofmann, and J. Sodroski. 1995. Replicative function and neutralization sensitivity of envelope glycoproteins from primary and T-cell line-passaged human immunodeficiency virus type 1 isolates. J. Virol. 69:4413-4422.
73. Taylor, R. 1994. Building a chemical barrier to HIV-1 transmission. J. NIH Res. 6:26-27.
74. The International Working Group on Vaginal Microbicides. 1996. Recommendations for the development of vaginal microbicides. AIDS 10:UN-AIDS1-UNAIDS6.
75. 73a. U. S. Department of Health and Human Services. 1996. AIDS research and reference reagent program catalog. National Institute of Allergy and Infectious Diseases, U. S. Department of Health & Human Services. Bethesda, Md.
76. von Brunn, A., M. Brand, C. Reichhuber, C. Morys-Wortman, F. Deinhardt, and F. Schödel. 1993a. Principal neutralizing domain of HIV-1 is highly immunogenic when expressed on the surface of hepatitis B core particles. Vaccine 11:817-824.
77. von Brunn, A., C. Reichhuber, M. Brand, B. Bechowsky, L. Gürtler, J. Eberle, A. Kleinschmidt, V. Erfle, and F. Schödel. 1993. The principal neutralizing domain (V3) of HIV-1 induces HIV-1-neutralizing antibodies upon expression on HbcAg particles, p. 159-165. In H. S. Ginsberg, F. Brown, R. M. Chanock, and R. A. Lerner (ed.), Vaccines 93. Cold Spring Harbor Press, Cold Spring Harbor, N.Y.
78. Weislow, O., R. Kiser, D. L. Fine, J. Bader, R. H. Shoemaker, and M. R. Boyd. 1989. New soluble-tormazan assay tor HIV-1 cytopathic effects: application to high-flux screening of synthetic and natural products for AIDS-antiviral activity. J. Natl. Cancer Inst. 81:577-586.
79. Weiss, R. A., and P. R. Clapham. 1996. Hot fusion of HIV. Nature 381:647-748.
80. White-Scharf, M. E., B. J. Potts, L. M. Smith, K. A. Sokolowski, J. R. Rusche, and S. Silver. 1993. Broadly neutralizing monoclonal antibodies to the V3 region of HIV-1 can be elicited by peptide immunization. Virology 192:197-206.
81. Zhang, L., Y. Huang, T. He, Y. Cao, and D. D. Ho. 1996. HIV-1 subtype and second-receptor use. Nature 383:768.